Prophylaxis News and Research

RSS

Women with chronic PVT should be informed, not discouraged, about pregnancy

Maternal and fetal outcomes are favorable for most pregnancies that reach 20 weeks’ in women with chronic portal vein thrombosis, a study shows.

13 Aug 2012

Pre-cesarean antibiotics cut infection risk

Administering prophylactic antibiotics before women undergo cesareans significantly reduces postsurgical infection rates, show US study findings.

9 Aug 2012

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

A pivotal clinical trial for an anti-rabies human monoclonal antibody (RMAb) being developed through a collaborative partnership between MassBiologics of the University of Massachusetts Medical School and the Serum Institute of India, Ltd., is starting to enroll patients.

8 Aug 2012

Mylan receives final FDA approval for Montelukast Sodium Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Montelukast Sodium Tablets, 10 mg, the generic version of Merck's Singulair Tablets.

7 Aug 2012

Access to dental care alone is not sufficient to meet oral health needs of adults with I/DD

A comprehensive study using electronic dental records to profile the oral health status of adults with intellectual and developmental disabilities (I/DD) has concluded that access to specialized dental care alone is not sufficient to meet the community's substantial oral health needs.

2 Aug 2012

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

31 Jul 2012

GlobalPost examines debate surrounding PrEP

GlobalPost's "Global Pulse" blog examines questions surrounding the use of the antiretroviral Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at high risk, as studies released and panel discussions held last week at the XIX International AIDS Conference (AIDS 2012) "raised concerns about the drug's effect on the future of the AIDS fight."

31 Jul 2012

Views on AIDS: More funding will be needed for new attack on HIV; The epidemic hits hard in the South

The international AIDS conference in Washington has already made two points clear. There is no prospect that scientists will any time soon find the ultimate solutions to the AIDS epidemic, namely a vaccine that would prevent infection with the AIDS virus or a "cure" for people already infected with the virus.

31 Jul 2012

Enoxaparin prevents PVT in advanced cirrhosis

Enoxaparin significantly reduces portal vein thrombosis and increases overall survival in patients with advanced cirrhosis, the results of an Italian study show.

30 Jul 2012

Letter to the editor: The role for pre-exposure prophylaxis in the fight against AIDS

This letter to Kaiser Health News responds to KHN's interview with Michael Weinstein, the president of the AIDS Healthcare Foundation.

27 Jul 2012

HIV drug resistance: an interview with Dr. Silvia Bertagnolio

Sexual intercourse is the major mode of HIV transmission. HIV may also be transmitted through sharing of needles or contaminated blood products (although this is rare).

27 Jul 2012

HPTN study results show additional benefits of early ART in HIV clinical outcomes

Study results released today by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes.

27 Jul 2012

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.

26 Jul 2012

Recent release: Blogs discuss advancements in HIV preventative, therapeutic R&D

In this post in the Center for Global Health Policy's "Science Speaks" blog, IAVI President and CEO Margaret McGlynn, AVAC Executive Director Mitchell Warren and UNAIDS Executive Director Michel Sidibe highlight the release of a report from the HIV Vaccine & Microbicides Resource Tracking Working Group.

26 Jul 2012

Dapivirine Phase III trial now underway in Africa to treat HIV in women

A large clinical trial testing the long-term safety and effectiveness of a new approach for preventing HIV in women - a vaginal ring used once a month - is now underway in Africa, researchers announced today at the XIX International AIDS Conference (AIDS 2012).

25 Jul 2012

Merck, Chimerix sign license agreement for CMX157 to treat HIV infection

Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclusive worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection.

24 Jul 2012

FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

Today, U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg announced the agency has approved or tentatively approved a total of 152 antiretroviral drugs in association with the President's Emergency Plan for AIDS Relief (PEPFAR) to treat those infected with HIV/AIDS in countries that lack the tools needed to fight the AIDS epidemic.

24 Jul 2012

Study shows disturbing rates of new HIV infections among U.S. black MSM

Study results released today by the HIV Prevention Trials Network (HPTN) show disturbing rates of new HIV infections occurring among black gay and bisexual men in the U.S. (also known as men who have sex with men, or MSM), particularly young black MSM.

24 Jul 2012

Implementing multifaceted global effort may help end global HIV/AIDS pandemic

Ending the global HIV/AIDS pandemic may be possible by implementing a multifaceted global effort that expands testing, treatment, and prevention programs, as well as meets the scientific challenges of developing an HIV vaccine and possibly a cure, according to a Viewpoint in the July 25 issue of JAMA, a theme issue on HIV/AIDS.

23 Jul 2012

Researchers identify high ARV drug exposure in hair samples of HIV uninfected infants

Researchers from the University of California, San Francisco (UCSF) and Makerere University in Uganda have used hair and blood samples from three-month old infants born to HIV-positive mothers to measure the uninfected babies' exposure—both in the womb and from breast-feeding—to antiretroviral medications their mothers were taking. The results, they said, are surprising.

23 Jul 2012